ClinicalTrials.gg
RecruitingNCT06536166BIGTIMUpdated May 29, 2026

Ruxolitinib Treatment in Inclusion Body Myositis

A Phase 2 interventional study of Ruxolitinib and Placebo in Inclusion Body Myositis, Sporadic, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 21 sites in France. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

Refer to the "Detailed Description" section.

Read the detailed description

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of Ruxolitinib in the Treatment of Subjects with Inclusion Body Myositis (IBM) IBM is the most frequent idiopathic immune myopathy (IIM) over age 45, pathologically characterized by the combination of intramuscular inflammation and degenerative features. It differs from other IIMs by its chronic evolution and refractoriness to common immunomodulatory drugs leading to marked disability and poor quality of life. Histological and molecular analyses of muscle biopsies from IBM patients showed intense muscular type II interferon (IFNγ) signature, stronger than observed in other IIMs. In vitro and in vivo experimental studies showed that IFNγ exerts myosuppressive effects through JAK/STAT pathway activation mimicking the degenerative features observed in IBM, and that these effects can be prevented by JAK-inhibitor ruxolitinib.

Hypothesis/Objective : Ruxolitinib could be an effective therapy for IBM. Objective is to evaluate its therapeutic effects in IBM.

Method : Comparative, multicenter, randomized, parallel-group, superiority, placebo-controlled, double-blind, phase 2 trial. 60 IBM patients able to walk during at least 6mn will be randomized in two groups (30/group) and received either ruxolitinib 15mgx2/d or placebo during 1 yr. Evaluation includes 6MWT, muscle strength quantification, functional scales, respiratory functional test and muscle MRI.

02

Conditions studied

  • Inclusion Body Myositis, Sporadic

Keywords

  • Inclusion body myositis
  • Idiopathic immune myopathy
  • JAK-inhibitor
  • Ruxolitinib
03

In context

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

This study's planned enrollment of 80 is above the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.

Browse Myositis, Inclusion Body studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 45 years
  • Effective for the duration of the clinical trial for fertile women of childbearing age
  • Defined diagnosis of IBM according to data-derived criteria (Llyod et al, 2014): Patient must fulfill the three following criteria for being diagnosed as IBM: (1) finger flexor or quadriceps weakness; and (2) muscle showing endomysial inflammation; and (3) muscle biopsy showing invasion of nonnecrotic muscle fibers or rimmed vacuoles
  • To be able to walk 6 min without assistance from another person (external assist devices permitted [e.g., canes, walkers, or rollators])
  • Patient informed and having signed the consent for participation, possibly assisted by a trusted person

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Patient under guardianship, curatorship, safeguard of justice or deprived of liberty
  • Patient with cognitive disorders or unable, according to the investigator, to understand the study and/or to give
  • Quadriceps weakness (manual muscle testing, MRC) below or equal 1
  • Forced vital capacity (FVC) or forced expiratory volume (FEV) \< 50% of predicted value
  • Concomitant use of immunomodulatory drugs including previous treatment with JAK inhibitor, or medications acting on muscle anabolism or catabolism
  • within the 4 weeks before starting treatment
  • Comorbidity or active chronic disease which contraindicate ruxolitinib:

    • Lipid parameters abnormalities/elevations
    • Severe renal impairment (stage 4) and end-stage renal disease (stage 5)
    • Hepatic impairment
    • Cytopenia
    • Recent history (\<6 months) of cardiovascular or thromboembolic disease (documented coronaropathy or hospitalization for acute arterial thrombosis or stroke or deep venous thrombosis or pulmonary embolism)
    • Active smoking more than 20 pack-years or history of respiratory or skin cancer or recent history (\<6 months) of other neoplastic disease
    • Very high cardiovascular risk (red color) at SCORE 2 in case of recent history (\<6 months) of cardiovascular or thromboembolic disease and non-controlled cardiovascular risk factors
    • History of Stevens-Johnson's syndrome or Lyell's syndrome
  • Active SARS-CoV-2 infection (patient can be included once infection resolved)
  • Any medical condition which limits the ability of participant to participate in study
  • Necessity to use a drug incompatible with ruxolitinib
  • to the IMP's active substance (ruxolitinib) or to any of the
  • Non-affiliation to a social security scheme or to another social protection scheme, patient on state medical aid
  • Foreseeable inability, according to the investigator, to participate in all the visits, treatments and measures provided for in the protocol
  • Concomitant participation in another clinical trial on medical product for human use, to a clinical investigation on a medical device, to interventional study involving human participants or in the exclusion period at the end of a previous clinical trial on medical product for human use, a clinical investigation on a medical device, or study involving human participants.

Participation in non-interventional research is permitted.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Randomization in experimental group.

    Drug: Ruxolitinib

  • Placebo comparator
    Control group

    Randomization in control group.

    Drug: Placebo

Interventions

  • IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.

  • DrugPlacebo

    IBM patients treated by placebo, twice a day, during 12 months.

06

What researchers measure

Primary outcomes

  1. 6 minutes-walk distance (6MWT): A distance walked in 6 min. superior in treated patients compared to placebo group

    The 6MWT is performed in a corridor, between two cones separated by a distance of 25 m.

    Time frame: 12 months

Secondary outcomes

  1. Adverse events (safety and tolerability) of ruxolitinib in IBM patients

    Adverse events collected according to the MedDRA classification

    Time frame: Through study completion that is to say 15 months

  2. Therapeutic muscular efficacy of ruxolitinib on muscle strength

    Quantification of muscle strength using dynamometer

    Time frame: Until last consultation that is to say 12 months

  3. Therapeutic muscular efficacy of ruxolitinib on overall muscle status

    Measurement of overall muscle status using scales and serum creatine kinase (CK) levels

    Time frame: Until last consultation that is to say 12 months

  4. Respiratory ability

    Forced vital capacity (FVC) measurement

    Time frame: 12 months

  5. Evaluate swallowing using Swallowing Disturbance Questionnaire (SDQ)

    Measurement of the swallowing disorders via Swallowing Disturbance Questionnaire (SDQ). 15 items. Overall score from 0,5 to 44,5. The score increase with the swallowing disorders.

    Time frame: 12 months

  6. Lower limb quantification of fat replacement of muscle tissue, residual muscle tissue and markers of disease activity using MRI

    Measurement of the differences in fat fraction value calculated on thigh Dixon MRI pictures

    Time frame: 12 months

  7. Evaluate quality of life using Health Assessment Questionnaire without Disability Index (HAQ-DI)

    Measurement of the difference in the quality of life measured by Health Assessment Questionnaire without Disability Index (HAQ-DI). 8 dimensions rated from 0 (without any difficulty) to 3 (unable to do). Overall score from 0 to 3. The higher the score, the lower the quality of life.

    Time frame: 12 months

  8. Evaluate quality of life using Duke health profile

    Measurement of the difference in the quality of life measured by Duke health profile - The Duke. 10 dimensions. Overall score from 0 to 100. The score increase with the quality of life.

    Time frame: 12 months

07

Study locations

15 of 21 sites recruiting
  • CHU d'Angers
    Angers, France 49100, France
    Enrolling by invitation
  • Centre hospitalier de la Côte Basque
    Bayonne, France 64109, France
    Enrolling by invitation
  • Hôpital CHU Jean Minjoz, CHU Besançon
    Besançon, France 25030, France
    Enrolling by invitation
  • Hôpital Pellegrin - Tripode, CHU de Bordeaux
    Bordeaux, France 33076, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital de la Cavale Blanche, CHU de Brest
    Brest, France 29200, France
    Enrolling by invitation
  • Hôpital Pierre Wertheimer, CHU de Lyon
    Bron, France 69500, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Caen Normandie
    Caen, France 14000, France
    Recruiting
  • Hôpital Henri-Mondor, APHP
    Créteil, France 94010, France
    Recruiting
  • Hôpital Raymond Poincaré, APHP
    Garches, France 92380, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Roger Salengro, CHU de Lille
    Lille, France 59037, France
    Recruiting
  • Hôpital Dupuytren, CHU de Limoges
    Limoges, France 87000, France
    Recruiting
  • Hôpital de la Timone, APHM
    Marseille, France 13005, France
    Not yet recruiting
  • Hôpital Gui de Chauliac, CHU de Montpellier
    Montpellier, France 34000, France
    Enrolling by invitation
  • CHU Nancy
    Nancy, France 54035, France
    Recruiting
  • Hôtel-Dieu, CHU Nantes
    Nantes, France 44093, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Pasteur, CHU de Nice
    Nice, France 06001, France
    Recruiting
  • Hôpital Pitié-Salpêtrière, APHP
    Paris, France 75013, France
    Recruiting
  • Hôpital Christian Cabrol, CHU Reims
    Reims, France 51100, France
    Recruiting
  • Hôpital Bellevue, CHU Saint-Etienne
    Saint-Etienne, France 42270, France
    Recruiting
  • Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg
    Strasbourg, France 67089, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Pierre-Paul Riquet, CHU de Toulouse
    Toulouse, France 31059, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Datas are own by assistance publique - hopitaux de paris, please contact sponsor for further information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2024
First posted
Aug 2, 2024
StartActual
May 27, 2025
Primary completionEst.
Jun 10, 2028
CompletionEst.
Sep 10, 2028
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06536166
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
May 27, 2025
Primary completion
Jun 10, 2028 (estimated)
Completion
Sep 10, 2028 (estimated)
Last update
May 29, 2026

Study contacts

François Jérôme AUTHIER, Pr
Contact
francois-jerome.authier@aphp.fr
+33 1 4981 2735
François Jérôme AUTHIER, Pr
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion